Alnylam and BridgeBio are competing for people who are switching from Pfizer’s blockbuster ATTR amyloidosis drug tafamidis while all three companies are fighting for new patients.

According to Benzinga Pro, Alnylam Pharmaceuticals's peer group average for short interest as a percentage of float is 5.87%, ...

BofA raised the firm’s price target on Alnylam (ALNY) to $328 from $325 and keeps a Buy rating on the shares. The firm updated models in ...

FDA accepts Regeneron's sBLA for Eylea HD in RVO with priority review; QUASAR data supports monthly dosing, target action date set for August 2025.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2025 on Thursday, May ...

In a report released today, Gena Wang from Barclays maintained a Buy rating on Legend Biotech (LEGN – Research Report), with a price target of ...

Detailed price information for Alnylam Pharmaceuticals (ALNY-Q) from The Globe and Mail including charting and trades.